T. Jeroen N. Hiltermann
University Medical Center Groningen · 277 works · 11,530 citations · h-index 41
Top works
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- Characteristics of the Inhibition of NADPH Oxidase Activation in Neutrophils by Apocynin, a Methoxy-Substituted Catechol
- Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
- 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
- The Effect of Inhaled Leukotriene D4 and Methacholine on Sputum Cell Differentials in Asthma
- NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
- Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
- Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor
- The detection of EpCAM+ and EpCAM– circulating tumor cells
- mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
- Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Non–Small-Cell Lung Cancer: The NVALT-4 Study
- A Qualitative Study of Serious Illness Conversations in Patients with Advanced Cancer
- Effects of Photochemical Air Pollution and Allergen Exposure on Upper Respiratory Tract Inflammation in Asthmatics
- Immune microenvironment composition in non‐small cell lung cancer and its association with survival
- COVID-19 vaccination: the VOICE for patients with cancer
- Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation
- Ozone-induced inflammation assessed in sputum and bronchial lavage fluid from asthmatics:
- Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study
- Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non–Small Cell Lung Cancer